Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,036 Brain Cancer
clinical trials

Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Toledo, OH
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Glendale, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Birmingham, AL
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
San Francisco, CA
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Precision Trial
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Precision Trial
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Aurora, CO
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Study of Lorlatinib (PF-06463922)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
San Francisco, CA
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Study of Lorlatinib (PF-06463922)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Study of Lorlatinib (PF-06463922)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Seattle, WA
Click here to add this to my saved trials
Brain Metastases Clinical Trial
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Status: Enrolling
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Oncology, Other Clinical Trial
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
MIBG With Dinutuximab
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
MIBG With Dinutuximab
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
MIBG With Dinutuximab
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Status: Enrolling, Phase
Updated: 1/5/2018
mi
from
Iowa City, IA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Norfolk, VA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Long Beach, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Tacoma, WA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Jackson, MS
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oakland, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Peoria, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Atlanta, GA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Durham, NC
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Madera, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orlando, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orlando, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Antonio, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Tacoma, WA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Jackson, MS
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oakland, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Peoria, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Durham, NC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Miami, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oakland, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Tampa, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Austin, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Birmingham, AL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Burlington, VT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Des Moines, IA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Portland, OR
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Akron, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Baltimore, MD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Charlotte, NC
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Danville, PA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Iowa City, IA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Long Beach, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Haven, CT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New Orleans, LA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Spokane, WA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Syracuse, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Washington DC,
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Norfolk, VA
Click here to add this to my saved trials
1 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 100